Chai Discovery
Category: AI in Biotech / Drug Discovery
An AI-powered platform for drug discovery that predicts and designs molecular structures and interactions. Chai Discovery was founded in 2024. The company is led by Joshua Meier. Based in San Francisco, United States. Team size: 11-50. Total funding raised: $225M. Latest round: Series B. Key investors include General Catalyst, Oak HC/FT, Menlo Ventures, Thrive Capital, OpenAI, Dimension, Neo, Yosemite, Lachy Groom, SV Angel, Glade Brook, Emerson Collective.
AMW Analysis
Chai Discovery operates an AI platform that predicts and designs molecular structures for drug discovery, aiming to compress development timelines from years to months. The company has rapidly scaled its funding and valuation over a short period. In December 2025, it closed a $130 million Series B at a $1.3 billion valuation, bringing total funding to $225 million. Shortly after, in January 2026, it announced a partnership with Eli Lilly to apply its Chai-2 algorithm to antibody design, shifting from trial-and-error to generative design with double-digit experimental hit rates. By July 2026, Chai Discovery raised an additional $400 million at a $3.8 billion valuation, tripling its worth in seven months, following a partnership with Novartis that validated the platform’s real-world utility. Total funding now exceeds $600 million across three rounds. The sequence of events—rapid financing, major pharma collaborations, and a steep valuation increase—indicates strong investor and industry confidence in the company’s AI-driven approach to drug discovery and its ability to secure high-value partnerships.
AMW analysis, generated from 4 tracked news signals.
- Founded
- 2024
- Headquarters
- San Francisco, United States
- Team size
- 11-50
- Total funding
- $225M
Value proposition
To significantly accelerate the drug discovery process from years to months by using AI to design and validate novel therapeutics for previously untreatable diseases.
Products and solutions
Chai-1, Chai-2
Unique value
Their AI models, Chai-1 and Chai-2, can perform unified predictions for a wide range of biomolecules (proteins, small molecules, DNA, RNA) and can generate and evaluate new molecular structures. They also offer a free web interface for their Chai-1 model.
Target customer
Pharmaceutical and biotechnology companies, researchers in drug discovery.
Industries served
Pharmaceuticals, Biotechnology, Healthcare
Technology advantage
The core advantage is the speed and accuracy of their AI platform in predicting molecular interactions, which drastically shortens the drug development timeline. Their models are described as 'state-of-the-art' and, in some cases, outperforming existing models like AlphaFold. The ability to design novel antibodies with Chai-2 is a significant leap.
How they differentiate
Chai Discovery differentiates itself through its advanced AI models, Chai-1 and Chai-2, which have demonstrated superior performance in predicting molecular structures and designing antibodies compared to competitors. The company claims a 19% success rate in antibody design, which is a significant improvement over previous benchmarks. They are also focused on open-sourcing some of their research to accelerate scientific progress.
Main competitors
Owkin, BenevolentAI, Formation Bio
Key partnerships
OpenAI, Thrive Capital, Menlo Ventures, DST Global Partners, Eli Lilly and Company
Notable customers
Eli Lilly and Company
Major milestones
Secured $70M in Series A funding., Developed and released Chai-1, an AI model for predicting molecular structures that outperforms Google DeepMind's AlphaFold on certain tasks., Launched Chai-2, an AI model for antibody design with a reported 19% success rate., Raised $130M Series B at $1.3B valuation, becoming an AI unicorn., Announced strategic collaboration with Eli Lilly and Company to accelerate biologics discovery.
Growth metrics
Specific growth metrics are not publicly available.
Market positioning
Chai Discovery is positioned as a cutting-edge AI-driven biotechnology company with a focus on developing foundational models for drug discovery. The company has gained significant attention for its technological advancements and strong backing from prominent investors, positioning it as a key innovator in the field.
Geographic focus
United States
Patents and IP
Information on specific patents is not publicly available at this time.
About Joshua Meier
Co-Founder at Chai Discovery, previously Senior Director of AI Research at Absci, Research Scientist at Meta, and Researcher at OpenAI.
Latest news about Chai Discovery
- Chai Discovery triples valuation to $3.8B in 7 months after raising $400M post-Novartis deal
- Chai Discovery has partnered with Eli Lilly to use its Chai-2 algorithm for antibody design, following a 130 million dollar Series B valuing the firm at 1.3 billion dollars. This collaboration shifts
- Eli Lilly has partnered with Chai Discovery to use the Chai-2 algorithm for antibody design, following Chai's 130 million dollar Series B at a 1.3 billion dollar valuation. This collaboration integrat
- OpenAI-backed Chai Discovery secured $130 million in Series B funding, reaching a $1.3 billion valuation. This rapid financing, totaling $225 million in three months, highlights significant investor c
More AI in Biotech / Drug Discovery companies
Official website: https://www.chaidiscovery.com/
